Department of Nephrology, West China Hospital, Sichuan University, 37# Guoxue Ally, Wuhou District, Chengdu City, Sichuan province, China.
Department of Medical Genetics, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, 37# Guoxue Ally, Wuhou District, Chengdu City, Sichuan province, China.
Biochem Biophys Res Commun. 2018 Nov 30;506(3):444-449. doi: 10.1016/j.bbrc.2018.10.102. Epub 2018 Oct 21.
AarF domain-containing kinase 4 (ADCK4)-associated glomerulopathy (ADCK4-GN) is an inherited mitochondrial nephropathy caused by mutations in the ADCK4 gene. Herein, we report a case of ADCK4-GN. The patient, a 14-year-old Chinese male, presented with asymptomatic proteinuria and steroid resistance. A renal biopsy showed focal segmental glomerulosclerosis (FSGS) and dysmorphic mitochondria in podocytes. Coenzyme Q10 treatment was partially effective. No adverse events were observed. Next generation and Sanger sequencing analyses revealed compound heterozygous mutations (c.625C > G, p.D209H and c.918G > T, p.C306X). Both inherited mutations are located in the highly conserved ABC1 domain. The unreported nonsense mutation causes a loss of 197 amino acids from the C-terminal portion of ADCK4, suggesting a deleterious effect of the truncating mutation by abolishing ADCK4 function. In conclusion, we identified a novel ABC1 domain-localized pathogenic mutation responsible for ADCK4-GN, further supporting the importance of the C-terminal portion of ADCK4. Next generation sequencing facilitated the early diagnosis. CoQ treatment may reduce proteinuria and postpone ADCK4-GN progression.
AarF 结构域含激酶 4(ADCK4)相关肾小球病(ADCK4-GN)是一种由 ADCK4 基因突变引起的遗传性线粒体肾病。在此,我们报告一例 ADCK4-GN 病例。患者为 14 岁中国男性,表现为无症状性蛋白尿和激素抵抗。肾活检显示局灶节段性肾小球硬化(FSGS)和足细胞中形态异常的线粒体。辅酶 Q10 治疗部分有效。未观察到不良反应。下一代和 Sanger 测序分析显示复合杂合突变(c.625C>G,p.D209H 和 c.918G>T,p.C306X)。这两个遗传突变都位于高度保守的 ABC1 结构域。未报道的无义突变导致 ADCK4 C 末端部分缺失 197 个氨基酸,表明截断突变通过破坏 ADCK4 功能产生有害影响。总之,我们鉴定了一个新的 ABC1 结构域局灶性致病性突变,导致 ADCK4-GN,进一步支持 ADCK4 C 末端部分的重要性。下一代测序有助于早期诊断。CoQ 治疗可能减少蛋白尿并延缓 ADCK4-GN 进展。